

Giuseppe Di Lorenzo

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1155717/giuseppe-di-lorenzo-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

274 papers	6,047 citations	44 h-index	61 g-index
311 ext. papers	7,139 ext. citations	4.5 avg, IF	5.45 L-index

#	Paper	IF	Citations
274	Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. <i>Annals of Oncology</i> , 2009 , 20, 1535-1542	10.3	155
273	Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. <i>European Journal of Cancer</i> , 2014 , 50, 1617-27	7.5	120
272	Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4469-74	2.2	114
271	Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. <i>European Urology</i> , 2008 , 54, 1089-94	10.2	106
270	Medical expulsive treatment of distal-ureteral stones using tamsulosin: a single-center experience. <i>Journal of Endourology</i> , 2006 , 20, 12-6	2.7	104
269	Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. <i>Cancer</i> , 2010 , 116, 1893-900	6.4	102
268	Management of AIDS-related Kaposi's sarcoma. <i>Lancet Oncology</i> , 2007 , 8, 167-76	21.7	101
267	Cyrus bipolar versus standard monopolar transurethral resection of the prostate: a randomized prospective trial. <i>Urology</i> , 2006 , 67, 69-72	1.6	97
266	Toxicities of targeted therapy and their management in kidney cancer. <i>European Urology</i> , 2011 , 59, 526-40	10.2	89
265	How to decrease pain during transrectal ultrasound guided prostate biopsy: a look at the literature. <i>Journal of Urology</i> , 2005 , 174, 2091-7	2.5	84
264	Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. <i>Lancet Oncology</i> , 2005 , 6, 295-300	21.7	82
263	Four-year outcome of a prospective randomised trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate. <i>European Urology</i> , 2009 , 55, 922-9	10.2	81
262	Epigenetic control of gene expression: Potential implications for cancer treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 111, 166-172	7	79
261	Castration-resistant prostate cancer: current and emerging treatment strategies. <i>Drugs</i> , 2010 , 70, 983-1000	10.0	77
260	Immunotherapy for the treatment of prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 551-61	19.4	74
259	Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. <i>PLoS ONE</i> , 2013 , 8, e67687	3.7	71
258	Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. <i>BJU International</i> , 2011 , 107, 234-9	5.6	71

257	A comprehensive outlook on intracerebral therapy of malignant gliomas. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 80, 54-68	7	70
256	Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. <i>Cancer</i> , 2008 , 112, 75-83	6.4	70
255	The use of tamsulosin in the medical treatment of ureteral calculi: where do we stand?. <i>Urological Research</i> , 2005 , 33, 460-4		70
254	Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options. <i>World Journal of Clinical Oncology</i> , 2011 , 2, 150-7	2.5	69
253	Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. <i>Annals of Oncology</i> , 2015 , 26, 2107-13	10.3	66
252	Clinicopathologic features of prostate adenocarcinoma incidentally discovered at the time of radical cystectomy: an evidence-based analysis. <i>European Urology</i> , 2007 , 52, 648-57	10.2	65
251	Penile cancer: current therapy and future directions. <i>Annals of Oncology</i> , 2013 , 24, 1179-89	10.3	61
250	Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and ChunH nomogram, two risk estimators incorporating prostate cancer antigen 3. <i>European Urology</i> , 2011 , 59, 81-7	10.2	59
249	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. <i>European Journal of Cancer</i> , 2013 , 49, 2134-42	7.5	55
248	Combination of perianal-intrarectal lidocaine-prilocaine cream and periprostatic nerve block for pain control during transrectal ultrasound guided prostate biopsy: a randomized, controlled trial. <i>Journal of Urology</i> , 2009 , 181, 585-91; discussion 591-3	2.5	53
247	Dynamic sentinel node biopsy in clinically node-negative penile cancer versus radical inguinal lymphadenectomy: a comparative study. <i>Urology</i> , 2005 , 66, 1282-6	1.6	53
246	Health related quality of life after radical cystectomy: comparison of ileal conduit to continent orthotopic neobladder. <i>European Journal of Surgical Oncology</i> , 2009 , 35, 858-64	3.6	52
245	Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. <i>Prostate</i> , 2013 , 73, 227-35	4.2	51
244	Are abstracts presented at the EAU meeting followed by publication in peer-reviewed journals? A critical analysis. <i>European Urology</i> , 2007 , 51, 833-40; discussion 840	10.2	51
243	Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. <i>Clinical Prostate Cancer</i> , 2003 , 2, 50-7		49
242	Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. <i>Annals of Surgical Oncology</i> , 2015 , 22, 2094-100	3.1	48
241	Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. <i>Clinica Chimica Acta</i> , 2012 , 413, 1274-8	6.2	48
240	Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. <i>European Urology</i> , 2011 , 60, 1280-4	10.2	48

239	Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. <i>European Urology</i> , 2010 , 58, 906-11	10.2	48
238	Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. <i>European Urology</i> , 2016 , 69, 634-641	10.2	47
237	Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. <i>BJU International</i> , 2012 , 110, E661-6	5.6	47
236	Metastatic renal cell carcinoma: recent advances in the targeted therapy era. <i>European Urology</i> , 2009 , 56, 959-71	10.2	47
235	Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. <i>Breast Cancer Research</i> , 2008 , 10, R60	8.3	47
234	The need to reduce patient discomfort during transrectal ultrasonography-guided prostate biopsy: what do we know?. <i>BJU International</i> , 2005 , 96, 977-83	5.6	45
233	Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells. <i>Cancer Biology and Therapy</i> , 2015 , 16, 567-79	4.6	44
232	Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi sarcoma: a multicenter study. <i>Journal of Investigative Dermatology</i> , 2008 , 128, 1578-80	4.3	44
231	Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance. <i>Oncotarget</i> , 2017 , 8, 18424-18434	3.3	44
230	The use of interferon in melanoma patients: a systematic review. <i>Cytokine and Growth Factor Reviews</i> , 2015 , 26, 203-12	17.9	43
229	Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. <i>Journal of Urology</i> , 2015 , 193, 41-7	2.5	43
228	New agents for prostate cancer. <i>Annals of Oncology</i> , 2014 , 25, 1700-1709	10.3	43
227	Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy. <i>Journal of Urology</i> , 2005 , 174, 2197-203	2.5	43
226	Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. <i>Journal of Urology</i> , 2016 , 195, 277-82	2.5	40
225	Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience. <i>Medicine (United States)</i> , 2015 , 94, e1861	1.8	39
224	Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2014 , 10, 975-83	3.6	38
223	Update on classic Kaposi sarcoma therapy: new look at an old disease. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 68, 242-9	7	38
222	Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. <i>BJU International</i> , 2012 , 110, 692-8	5.6	37

221	The emerging role of obesity, diet and lipid metabolism in prostate cancer. <i>Future Oncology</i> , 2017 , 13, 285-293	3.6	37
220	Thermal and fluid dynamic behaviors of confined laminar impinging slot jets with nanofluids. <i>International Communications in Heat and Mass Transfer</i> , 2016 , 70, 15-26	5.8	36
219	The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 86, 42-51	7	36
218	Testicular cancer from diagnosis to epigenetic factors. <i>Oncotarget</i> , 2017 , 8, 104654-104663	3.3	36
217	Complications and quality of life in elderly patients with several comorbidities undergoing cutaneous ureterostomy with single stoma or ileal conduit after radical cystectomy. <i>BJU International</i> , 2016 , 118, 521-6	5.6	36
216	Imatinib mesylate in thymic epithelial malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 309-15	3.5	35
215	Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). <i>Annals of Oncology</i> , 2010 , 21, 1168-1172	10.3	35
214	Nonmotor Symptoms in Parkinson Disease: A Descriptive Review on Social Cognition Ability. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2017 , 30, 109-121	3.8	34
213	Sipuleucel-T (Provenge®) for castration-resistant prostate cancer. <i>BJU International</i> , 2012 , 110, E99-104	5.6	34
212	Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell-Renal Cell Carcinoma. <i>Medicine (United States)</i> , 2015 , 94, e2117	1.8	34
211	Management of gynaecomastia in patients with prostate cancer: a systematic review. <i>Lancet Oncology</i> , 2005 , 6, 972-9	21.7	34
210	Locally advanced nasopharyngeal carcinoma: Current and emerging treatment strategies. <i>World Journal of Clinical Oncology</i> , 2011 , 2, 377-83	2.5	31
209	Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. <i>World Journal of Urology</i> , 2020 , 38, 143-150	4	31
208	BAG3 protein delocalisation in prostate carcinoma. <i>Tumor Biology</i> , 2010 , 31, 461-9	2.9	30
207	Expression of proto-oncogene c-kit in high risk prostate cancer. <i>European Journal of Surgical Oncology</i> , 2004 , 30, 987-92	3.6	30
206	Coronavirus Disease (COVID-19) in Italy: Analysis of Risk Factors and Proposed Remedial Measures. <i>Frontiers in Medicine</i> , 2020 , 7, 140	4.9	29
205	The therapy of kidney cancer with biomolecular drugs. <i>Cancer Treatment Reviews</i> , 2010 , 36 Suppl 3, S16-24	2.4	29
204	Predicting Pathological Features at Radical Prostatectomy in Patients with Prostate Cancer Eligible for Active Surveillance by Multiparametric Magnetic Resonance Imaging. <i>PLoS ONE</i> , 2015 , 10, e0139696	3.7	29

203	Metabolomic profiling for the identification of novel diagnostic markers and therapeutic targets in prostate cancer: an update. <i>Expert Review of Molecular Diagnostics</i> , 2019 , 19, 377-387	3.8	28
202	A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. <i>BJU International</i> , 2014 , 113, E137-43	5.6	28
201	New perspectives in the therapy of castration resistant prostate cancer. <i>Current Drug Targets</i> , 2012 , 13, 1676-86	3	28
200	Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial. <i>Cancer Biology and Therapy</i> , 2007 , 6, 313-7	4.6	28
199	Biomarkers in localized prostate cancer. <i>Future Oncology</i> , 2016 , 12, 399-411	3.6	27
198	Increased risk of bladder cancer in critical areas at high pressure of pollution of the Campania region in Italy: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 534-41	7	27
197	Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2013 , 9, 889-97	3.6	27
196	Quantitative analysis of pursuit ocular movements in Parkinson's disease by using a video-based eye tracking system. <i>European Neurology</i> , 2007 , 58, 193-7	2.1	27
195	Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease. <i>Prostate Cancer and Prostatic Diseases</i> , 2005 , 8, 54-9	6.2	27
194	Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 459-464	2.8	26
193	Concurrent chemoradiotherapy for men with locally advanced penile squamous cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 440-6	3.3	26
192	Combination of docetaxel and cetuximab for penile cancer: a case report and literature review. <i>Anti-Cancer Drugs</i> , 2012 , 23, 573-7	2.4	26
191	Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retrospective study. <i>Journal of Translational Medicine</i> , 2013 , 11, 161	8.5	25
190	Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 501-8	2.8	25
189	Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 25-8	3.5	25
188	Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study. <i>Cancer</i> , 2008 , 112, 1147-52	6.4	25
187	Efficacy of rituximab in gastric diffuse large B cell lymphoma patients. <i>World Journal of Gastroenterology</i> , 2010 , 16, 2526-30	5.6	25
186	Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 548-555.e324	3.3	24

185	The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. <i>European Urology</i> , 2012 , 61, 639-47	10.2	24
184	FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. <i>Japanese Journal of Clinical Oncology</i> , 2004 , 34, 747-50	2.8	24
183	Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014 , 33, 48	12.8	23
182	Pegylated liposomal doxorubicin in stage IVB mycosis fungoides. <i>British Journal of Dermatology</i> , 2005 , 153, 183-5	4	23
181	COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 152, 102991	7	23
180	Peg-filgrastim and cabazitaxel in prostate cancer patients. <i>Anti-Cancer Drugs</i> , 2013 , 24, 84-9	2.4	22
179	Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 1455-61	3.5	22
178	Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice. <i>European Urology</i> , 2010 , 58, 636-7	10.2	22
177	Statistical design in phase II clinical trials and its application in breast cancer. <i>Lancet Oncology</i> , 2003 , 4, 305-11	21.7	22
176	Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2014 , 10, 1353-60	3.6	21
175	Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial. <i>Future Oncology</i> , 2014 , 10, 2141-7	3.6	21
174	Magnetic resonance spectroscopy: an in vivo molecular imaging biomarker for Parkinson's disease?. <i>BioMed Research International</i> , 2014 , 2014, 519816	3	21
173	Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib. <i>Value in Health</i> , 2011 , 14, 846-51	3.3	21
172	Pathology of the prostate in radical cystectomy specimens: a critical review. <i>Surgical Oncology</i> , 2009 , 18, 73-84	2.5	21
171	Role of dynamic sentinel node biopsy in penile cancer: our experience. <i>Journal of Surgical Oncology</i> , 2006 , 93, 181-5	2.8	21
170	Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 1400	5.3	21
169	Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guérin-induced toxicity?. <i>BJU International</i> , 2009 , 104, 633-9	5.6	20
168	An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 1491-7	4	20

167	Vesicourethral anastomosis during radical retropubic prostatectomy: does the number of sutures matter?. <i>Urology</i> , 2007 , 69, 547-51	1.6	20
166	Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis. <i>Oncotarget</i> , 2017 , 8, 100708-100716	3.3	20
165	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. <i>JAMA Network Open</i> , 2020 , 3, e2021692	10.4	19
164	Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020 , 12,	6.6	19
163	Gynecomastia in patients with prostate cancer: update on treatment options. <i>Prostate Cancer and Prostatic Diseases</i> , 2006 , 9, 109-14	6.2	19
162	Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients. <i>Cancer</i> , 2009 , 115, 517-23	6.4	18
161	Recovery of erection after pelvic urologic surgery: our experience. <i>International Journal of Impotence Research</i> , 2005 , 17, 484-93	2.3	18
160	Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder Cancer. <i>Journal of Cancer</i> , 2018 , 9, 4250-4254	4.5	18
159	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. <i>Oncotarget</i> , 2018 , 9, 19861-19873	3.3	17
158	Poor survival in prostate cancer patients with primary refractoriness to docetaxel. <i>European Urology</i> , 2014 , 65, 505-7	10.2	17
157	What happens to the abstracts presented at the Societ�Internationale dUrologie meeting?. <i>Urology</i> , 2008 , 71, 367-71	1.6	17
156	Adrenal sparing surgery in the treatment of renal cell carcinoma: when is it possible?. <i>World Journal of Urology</i> , 2003 , 21, 153-8	4	17
155	Are extended biopsies really necessary to improve prostate cancer detection?. <i>Prostate Cancer and Prostatic Diseases</i> , 2003 , 6, 250-5	6.2	17
154	Squamous cell carcinoma of the scrotum: A look beyond the chimneystacks. <i>World Journal of Clinical Cases</i> , 2014 , 2, 654-60	1.6	17
153	Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. <i>Future Oncology</i> , 2015 , 11, 3091-8	3.6	16
152	Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 495-500	3.3	16
151	Combination therapy for metastatic renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2016 , 4, 100	3.2	16
150	The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 1387-1401	5.4	16

149	The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer. <i>Drugs</i> , 2019 , 79, 381-400	12.1	15
148	Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. <i>European Urology Focus</i> , 2018 , 4, 874-879	5.1	15
147	Myrtucommulone production by a strain of <i>Neofusicoccum australe</i> endophytic in myrtle (<i>Myrtus communis</i>). <i>World Journal of Microbiology and Biotechnology</i> , 2014 , 30, 1047-52	4.4	15
146	Matrix metalloproteinase-2 and -9 in the urine of prostate cancer patients. <i>Oncology Reports</i> , 2010 , 24, 3-8	3.5	15
145	Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports. <i>World Journal of Clinical Cases</i> , 2014 , 2, 228-31	1.6	15
144	Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 761-5	2.8	14
143	Metabolic syndrome as a peculiar target for management of prostate cancer patients. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 211-20	3.3	14
142	Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial. <i>Anti-Cancer Drugs</i> , 2010 , 21, 101-6	2.4	14
141	Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer. <i>European Urology</i> , 2004 , 46, 712-6	10.2	14
140	Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study. <i>Frontiers in Pharmacology</i> , 2016 , 7, 487	5.6	14
139	Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study. <i>Medicine (United States)</i> , 2015 , 94, e2297	1.8	13
138	Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments. <i>Current Urology Reports</i> , 2013 , 14, 174-83	2.9	13
137	Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms. <i>Oncology Reports</i> , 2012 , 27, 409-15	3.5	13
136	Hormone-refractory prostate cancer: where are we going?. <i>Drugs</i> , 2007 , 67, 1109-24	12.1	13
135	Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. <i>European Urology</i> , 2007 , 52, 1020-7	10.2	13
134	Role of chemotherapy in hormone-refractory prostate cancer. Old issues, recent advances and new perspectives. <i>Urologia Internationalis</i> , 2003 , 70, 1-14	1.9	13
133	Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. <i>Medicine (United States)</i> , 2016 , 95, e2299	1.8	13
132	Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019 , 11,	6.6	12

131	Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 178-84	3.3	12
130	Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial. <i>Frontiers in Pharmacology</i> , 2018 , 9, 189	5.6	12
129	EGFR mutational status in penile cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2013 , 17, 501-5	6.4	12
128	Preoperative insulin-like growth factor-binding protein-3 (IGFBP-3) blood level predicts gleason sum upgrading. <i>Prostate</i> , 2012 , 72, 100-7	4.2	12
127	Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer. <i>Urology</i> , 2007 , 69, 347-51	1.6	12
126	Prospective clinical trials of biotherapies in solid tumors: a 5-year survey. <i>Cancer Immunology, Immunotherapy</i> , 2005 , 54, 44-50	7.4	12
125	Complete Response and Fatigue Improvement With the Combined Use of Cyclophosphamide and Quercetin in a Patient With Metastatic Bladder Cancer: A Case Report. <i>Medicine (United States)</i> , 2016 , 95, e2598	1.8	12
124	Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 395-8	3.3	11
123	Combined chemo-radiotherapy in locally advanced nasopharyngeal carcinomas. <i>World Journal of Clinical Oncology</i> , 2013 , 4, 47-51	2.5	11
122	Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 151, 102992	7	11
121	First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103198	7	11
120	Cosmic radiation and cancer: is there a link?. <i>Future Oncology</i> , 2015 , 11, 1123-35	3.6	10
119	Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016 , 7, 33381-90	3.3	10
118	Update on PEG-interferon β as adjuvant therapy in melanoma. <i>Anticancer Research</i> , 2012 , 32, 3901-9	2.3	10
117	Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 71-9	3.3	9
116	It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature. <i>BMC Cancer</i> , 2018 , 18, 146	4.8	9
115	Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis. <i>Future Oncology</i> , 2015 , 11, 3159-66	3.6	9
114	Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma. <i>Journal of Urology</i> , 2015 , 193, 1905-10	2.5	9

113	Numerical Study of Laminar Confined Impinging Slot Jets with Nanofluids. <i>Advances in Mechanical Engineering</i> , 2012 , 4, 248795	1.2	9
112	Adrenalectomy: defining its role in the surgical treatment of renal cell carcinoma. <i>Urologia Internationalis</i> , 2003 , 71, 361-7	1.9	9
111	Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies. <i>World Journal of Clinical Oncology</i> , 2012 , 3, 111-5	2.5	9
110	Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 331-40	3.3	9
109	Modelling of a Hybrid-Electric Light Aircraft. <i>Energy Procedia</i> , 2017 , 126, 1155-1162	2.3	8
108	Optimal management of a patient with recurrent nasopharyngeal carcinoma. <i>World Journal of Clinical Cases</i> , 2014 , 2, 297-300	1.6	8
107	Non-AIDS-related Kaposi's sarcoma: A single-institution experience. <i>World Journal of Clinical Oncology</i> , 2013 , 4, 52-7	2.5	8
106	Kaempferol, Myricetin and Fisetin in Prostate and Bladder Cancer: A Systematic Review of the Literature. <i>Nutrients</i> , 2021 , 13,	6.7	8
105	Development of a Lumped Parameter Model for an Aeronautic Hybrid Electric Propulsion System. <i>Aerospace</i> , 2018 , 5, 105	2.5	8
104	Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results. <i>Journal of Translational Medicine</i> , 2019 , 17, 296	8.5	7
103	Everolimus as second-line therapy for metastatic renal cell carcinoma: a Real-life study. <i>Future Oncology</i> , 2015 , 11, 219-24	3.6	7
102	Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). <i>Tumori</i> , 2019 , 105, 3-12	1.7	7
101	Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib. <i>Canadian Urological Association Journal</i> , 2014 , 8, E121-5	1.2	7
100	Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients. <i>Anti-Cancer Drugs</i> , 2009 , 20, 277-80	2.4	7
99	Retrospective observational study of sunitinib administered on schedule 2/1 in patients with metastatic renal cell carcinoma (mRCC): The rainbow study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 471-477	4.7	7
98	Liquid biopsy in bladder cancer: State of the art and future perspectives.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 170, 103577	7	7
97	High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial. <i>Medicine (United States)</i> , 2018 , 97, e11254	1.8	7
96	Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 265.e15-21	2.8	6

95	Rapidly progressive disease in a castration-resistant prostate cancer patient after cabazitaxel discontinuation. <i>Anti-Cancer Drugs</i> , 2015 , 26, 236-9	2.4	6
94	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. <i>Future Oncology</i> , 2016 , 12, 493-502	3.6	6
93	Assessment of Total, PTEN, and AR-V7 Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, e286-e298	3.3	6
92	Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 250-6	3.3	5
91	Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content. <i>Oncology Reports</i> , 2010 , 24, 213-7	3.5	5
90	Is There a Standard Chemotherapeutic Regimen for Hormone-Refractory Prostate Cancer? Present and Future Approaches in the Management of the Disease. <i>Tumori</i> , 2003 , 89, 349-360	1.7	5
89	Real-world experience with cabazitaxel in patients with metastatic castration-resistant prostate cancer: a final, pooled analysis of the compassionate use programme and early access programme. <i>Oncotarget</i> , 2019 , 10, 4161-4168	3.3	5
88	Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016 , 16, 1113-1120	3.8	5
87	Locally advanced paranasal sinus carcinoma: A study of 30 patients. <i>Oncology Letters</i> , 2017 , 13, 1338-1342	4.2	4
86	The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Cancer</i> , 2017 , 8, 2663-2668	4.5	4
85	A Challenging Surgical Approach to Locally Advanced Primary Urethral Carcinoma: A Case Report and Literature Review. <i>Medicine (United States)</i> , 2016 , 95, e3642	1.8	4
84	Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen. <i>OncoTargets and Therapy</i> , 2015 , 8, 1345-9	4.4	4
83	Tumor-to-tumor metastasis: breast cancer metastatic to thymic epithelial tumor. <i>Anti-Cancer Drugs</i> , 2013 , 24, 759-64	2.4	4
82	Targeted therapy in the treatment of metastatic renal cell cancer. <i>Oncology</i> , 2009 , 77 Suppl 1, 122-31	3.6	4
81	Soluble interleukin-6 receptor to interleukin-6 (sIL-6R/IL-6) ratio in serum as a predictor of high Gleason sum at radical prostatectomy. <i>Oncology Letters</i> , 2011 , 2, 861-864	2.6	4
80	Ten-year adjuvant treatment with somatostatin analogs in a patient with atypical carcinoid of the lung. <i>Anti-Cancer Drugs</i> , 2010 , 21, 465-8	2.4	4
79	Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?. <i>Journal of Neuro-Oncology</i> , 2010 , 100, 311-9	4.8	4
78	Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019 , 71, 445-456	4.4	4

77	Activity and safety of pegylated liposomal doxorubicin,5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study. <i>World Journal of Gastroenterology</i> , 2007 , 13, 6553	5.6	4
76	Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis. <i>Frontiers in Oncology</i> , 2021 , 11, 651745	5.3	4
75	Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials. <i>World Journal of Urology</i> , 2019 , 37, 1049-1059	4	4
74	Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 425-433	3.3	4
73	Re: Silke Gillesen Sommer, Thomas Powles. Advice for Medical Oncology Care of Urological Cancer Patients During the COVID-19 Pandemic. Eur Urol 2020;78:e2-3: Is It Always Correct to Continue Androgen Receptor Signaling Inhibitors in the COVID-19 Era?. <i>European Urology</i> , 2020 , 78, e10-e11	10.2	3
72	Words of wisdom: Re: Abiraterone in metastatic prostate cancer without previous chemotherapy. <i>European Urology</i> , 2013 , 63, 961	10.2	3
71	Preliminary safety results of an Italian early-access program (EAP) with cabazitaxel plus prednisone (CbzP) in patients with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 253-253	2.2	3
70	The Sooner, the Better: The Establishment of a Treatment Paradigm in Prostate Cancer. <i>Frontiers in Pharmacology</i> , 2017 , 8, 788	5.6	2
69	Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 185-92	3.3	2
68	Using cumulative toxicity to identify the optimal second-line targeted therapy in patients with metastatic renal cell carcinoma: what's new?. <i>Future Oncology</i> , 2014 , 10, 845-50	3.6	2
67	Comment on: EGFR mutational status in Brazilian patients with penile carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2013 , 17, 857-9	6.4	2
66	Authors reply: an adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1079-1080	4	2
65	Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer. <i>World Journal of Surgical Oncology</i> , 2010 , 8, 8	3.4	2
64	Estramustine in prostate cancer: new look at an old drug. <i>Lancet Oncology</i> , 2007 , 8, 959-61	21.7	2
63	Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis.. <i>European Urology</i> , 2022 ,	10.2	2
62	Capecitabine plus gemcitabine in thymic epithelial tumors: Final analysis of a phase II trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7528-7528	2.2	2
61	Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 92-92	2.2	2
60	Health-related quality of life in Parkinson's disease patients in northeastern Sicily, Italy: (An ecological perspective). <i>Neural Regeneration Research</i> , 2013 , 8, 1615-22	4.5	2

59	Hematological Toxicity During Concomitant Treatment With Ruxolitinib and Avelumab for Merkel Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020 , 10, 579914	5.3	2
58	Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature. <i>Medicine (United States)</i> , 2016 , 95, e2754	1.8	2
57	Genetics and management of locally advanced carcinomas of the head and neck: role of altered fractionation radiotherapy. <i>Future Science OA</i> , 2019 , 5, FSO347	2.7	2
56	A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy. <i>Future Oncology</i> , 2021 , 17, 3987-3994	3.6	2
55	Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. <i>Tumori</i> , 2003 , 89, 349-60	1.7	2
54	PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study. <i>Medicine (United States)</i> , 2017 , 96, e6817	1.8	1
53	The expanding role of chemotherapy in prostate cancer. <i>Future Oncology</i> , 2015 , 11, 2637-2640	3.6	1
52	Re: Olaparib for Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2020 , 78, 767-768	10.2	1
51	Management of Ewing Sarcoma Family of Tumors: A Short Description of a Rare Primitive Uterine pPNET and Literature Review. <i>OncoTargets and Therapy</i> , 2020 , 13, 1179-1184	4.4	1
50	Hypercastration in prostate cancer. <i>Expert Review of Endocrinology and Metabolism</i> , 2013 , 8, 303-305	4.1	1
49	Looking at the prostates of patients with bladder cancer: a thoughtful exercise. <i>BJU International</i> , 2009 , 104, 160-2	5.6	1
48	How to carry out retrospective studies in metastatic renal cell cancer: two caveats that should be avoided. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 331-3	3.5	1
47	Re: Abstracts presented at the American Urological Association Annual Meeting: determinants of subsequent peer reviewed publication: C. C. Hoag, D. S. Elterman and A. E. MacNeily. J Urol 2006; 176: 2624-2629. Re: Factors associated with the full publication of studies presented in abstract form at the annual meeting of the American Urological Association: Smith WA, Cangel QV, Tseng	2.5	1
46	Re: Fabio Calabro and Cora N. Sternberg. Current indications for chemotherapy in prostate cancer patients. Eur urol 2007;51:17-26. <i>European Urology</i> , 2007 , 52, 613-4	10.2	1
45	Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 336-336	2.2	1
44	Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 353-353	2.2	1
43	Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15594-e15594	2.2	1
42	Impact of new agents (NAs) on post-docetaxel (DOC) survival of octogenarians with metastatic castration resistant prostate cancer (mCRPC) patients (pts): Results of an Italian multicenter retrospective study (DELPHI study).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16017-e16017	2.2	1

41	Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 311-311	2.2	1
40	First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 432-432	2.2	1
39	Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 431-431 ²	2.2	1
38	Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 494-498	3.3	1
37	Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry. <i>Cancers</i> , 2020 , 12,	6.6	1
36	A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone for second-line chemotherapy in men with metastatic castrate resistant prostate cancer (mCRPC): CABACARE.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS387-TPS387	2.2	0
35	Coronavirus Disease 2019 Emergency and Cancer in the South of Italy: What's New for the Oncologist?. <i>Frontiers in Medicine</i> , 2020 , 7, 189	4.9	0
34	Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 318-318	2.2	0
33	Re: Matthew R. Smith, Maha Hussain, Fred Saad, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. <i>N Engl J Med</i> . In press. https://doi.org/10.1056/NEJMoa2119115 .. <i>European Urology</i> , 2022 , 82, e17-e17	10.2	0
32	Words of Wisdom. Re: Androgen Deprivation Therapy plus Docetaxel and Estramustine Versus Androgen Deprivation Therapy Alone for High-risk Localised Prostate Cancer (GETUG 12): A Phase 3 Randomised Controlled Trial. <i>European Urology</i> , 2015 , 68, 1098-9	10.2	
31	Re: Sequential sorafenib and sunitinib for renal cell carcinoma M. P. Sablin, S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier, J. Gautier, C. Celier, J. Medioni and B. Escudier <i>J Urol</i> 2009; 182: 29-34. <i>Journal of Urology</i> , 2010 , 183, 824-5; author reply 825	2.5	
30	Editorial comment. Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes. <i>Urology</i> , 2010 , 76, 1076; author reply 1076-7	1.6	
29	Re: Björn Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell carcinoma guideline. <i>Eur Urol</i> 2007;51:1502-10. <i>European Urology</i> , 2007 , 52, 926-8; author reply 928	10.2	
28	A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone in docetaxel-pretreated men with metastatic castration resistant prostate cancer (mCRPC): The CABACARE trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS345-TPS345	2.2	
27	Chemoradiation for locally advanced penile squamous cell carcinoma (PSCC): A multi-institution retrospective study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15616-e15616	2.2	
26	Treatment and outcome(s) of a large cohort of Italian patients (pts) with poor-risk metastatic renal cell carcinoma (prRCC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15568-e15568	2.2	
25	Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4514-4514	2.2	
24	A case series of low-dose sorafenib plus tamoxifen in sorafenib-pretreated patients with advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15139-e15139	2.2	

- 23 A proposed new model for prognostic stratification of poor-risk patients with metastatic renal cell carcinoma (mRCC) in the era of targeted therapy.. *Journal of Clinical Oncology*, **2014**, 32, e15588-e15588^{2,2}
- 22 Prognostic factors in patients with pancreatic metastases from renal cell carcinoma (PM-RCC): Room for thinking about the role of surgery?. *Journal of Clinical Oncology*, **2014**, 32, e15563-e15563 2.2
- 21 Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy.. *Journal of Clinical Oncology*, **2015**, 33, 335-335 2.2
- 20 Safety of cisplatin in patients with urothelial carcinoma (UC) and renal dysfunction.. *Journal of Clinical Oncology*, **2015**, 33, 321-321 2.2
- 19 Multivariable analysis of predictors of side effects of cabazitaxel in the Italian Expanded Access Program.. *Journal of Clinical Oncology*, **2015**, 33, 225-225 2.2
- 18 Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. *Journal of Clinical Oncology*, **2015**, 33, 4527-4527^{2,2}
- 17 Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. *Journal of Clinical Oncology*, **2016**, 34, 386-386 2.2
- 16 Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide.. *Journal of Clinical Oncology*, **2017**, 35, e16503-e16503 2.2
- 15 Thalidomide and Analogs **2010**, 215-223
- 14 Decision making in clinical stage I (CSI) testicular cancer (TC).. *Journal of Clinical Oncology*, **2012**, 30, e15034-e15034^{2,2}
- 13 The burden of illness in metastatic renal cell carcinoma (mRCC) patients after two targeted therapies: A review of the literature.. *Journal of Clinical Oncology*, **2012**, 30, e15043-e15043 2.2
- 12 Updated safety result of a large Italian early access program (EAP) with cabazitaxel plus prednisone (CbzP) in metastatic castration-resistant prostate cancer (mCRPC) patients who progressed during or after docetaxel (D) therapy.. *Journal of Clinical Oncology*, **2012**, 30, e15185-e15185 2.2
- 11 Prognostic factors and validation of prognostic nomograms in patients (pts) treated with three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC): Results from an Italian survey.. *Journal of Clinical Oncology*, **2013**, 31, 470-470 2.2
- 10 Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP).. *Journal of Clinical Oncology*, **2013**, 31, 189-189 2.2
- 9 Impact of response to prior chemotherapy (RTPC) on outcomes in second-line therapy for advanced urothelial carcinoma (UC): Implications for trial design.. *Journal of Clinical Oncology*, **2013**, 31, 4539-4539^{2,2}
- 8 Capecitabine-gemcitabine in thymic epithelial tumors.. *Journal of Clinical Oncology*, **2013**, 31, e18536-e18536^{2,2}
- 7 Thymic epithelial tumors at University Federico II of Naples: A 30-year experience.. *Journal of Clinical Oncology*, **2013**, 31, 7603-7603 2.2
- 6 Potential predictive and prognostic factors for sequential treatment with abiraterone acetate and cabazitaxel in metastatic docetaxel-refractory castration-resistant prostate cancer (mDR-CRPC).. *Journal of Clinical Oncology*, **2013**, 31, e16093-e16093 2.2

- 5 Clinical outcome (CO) and predictive factors (PRE) evaluation of young (≤60 years) castration-resistant prostate cancer (CRPC) patients, treated with docetaxel (DOC): Preliminary results of an Italian multicenter retrospective study (CYCLOP study).. *Journal of Clinical Oncology*, **2013**, 31, e16031-e16031 2.2
- 4 Clinical outcomes of patients (pts) age 60 or younger treated with docetaxel (DOC) for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (CYCLOP study).. *Journal of Clinical Oncology*, **2014**, 32, 214-214 2.2
- 3 Cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D): Analysis by age group.. *Journal of Clinical Oncology*, **2014**, 32, 109-109 2.2
- 2 Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma.. *Journal of Clinical Oncology*, **2014**, 32, 421-421 2.2
- 1 Integrated comprehensive high-throughput kinomics profiling and whole exome sequencing of penile squamous cell cancer (PSCC).. *Journal of Clinical Oncology*, **2014**, 32, 383-383 2.2